Title: Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Abstract:
Extracellular Vesicles (EVs) are lipid bilayer–enclosed nanoparticles released by virtually all cells and are now recognized as key mediators of intercellular communication. Their capacity to transfer lipids, proteins, nucleic acids, and metabolites has spurred intense interest in both diagnostics and therapeutics across oncology, immunology, regenerative medicine, and neurosciences. EVs mirror the molecular signatures of their parental cells and can engage specific receptors on recipient cells, enabling targeted delivery and uptake. Coupled with their biocompatibility, low immunogenicity, stability, and ability to cross biological barriers, these properties have positioned EVs as promising nanocarriers. Nevertheless, the clinical translation of EV-based therapies is limited by challenges in scalable production, purity and batch consistency, endogenous cargo–related safety concerns, and the coexistence of native and exogenous payloads after engineering.
Here, I present an innovative, fast, reproducible, and sustainable strategy for EV engineering based on osmotic lysis. In this approach, EVs isolated via standard methods are rapidly diluted in a hypotonic aqueous solution to induce controlled membrane disruption through ionic imbalance, followed by spontaneous reassembly into structurally stable nanovesicles. This process yields vesicle populations with higher particle concentration and improved purity while efficiently removing intraluminal cargo such as proteins and nucleic acids that may be associated with tumorigenic or immunogenic risk. By decoupling native cargo from the engineered product, the method mitigates safety liabilities and enables concurrent loading of exogenous therapeutic payloads without interference from endogenous material. Notably, the lipid–protein rearrangements occurring during lysis and reassembly enhance cellular uptake, particularly in tumor cells, suggesting improved targeting specificity.
Overall, osmotic lysis–driven EV engineering offers a versatile and scalable route to generate functional, customizable, and clinically oriented EV-based nanocarriers. The approach directly addresses key bottlenecks in yield, purity, and safety, and supports the rational design of next-generation EV therapeutics for drug delivery and diagnostic applications.
